Inhibition of RhoA pathway rescues the endocytosis defects in Oligophrenin1 mouse model of mental retardation.

Malik Khelfaoui, Alice Pavlowsky, Andrew Powell, Pamela Valnegri, Kenneth Cheong, Yann Blandin, Maria Passafaro, John Jefferys, Jamel Chelly, Pierre Billuart

To cite this version:
Malik Khelfaoui, Alice Pavlowsky, Andrew Powell, Pamela Valnegri, Kenneth Cheong, et al.. Inhibition of RhoA pathway rescues the endocytosis defects in Oligophrenin1 mouse model of mental retardation.. Human Molecular Genetics, Oxford University Press (OUP), 2009, 18 (14), pp.2575-83. <10.1093/hmg/ddp189>. <inserm-00424014>
Inhibition of RhoA pathway rescues the endocytosis defects in Oligophrenin1 mouse model of mental retardation

Malik Khelfaoui1,2, Alice Pavlowsky1,2, Andrew D. Powell3, Pamela Valnegri4, Kenneth W. Cheong3, Yann Blandin1,2, Maria Passafaro4, John G.R. Jefferys3, Jamel Chelly1,2 and Pierre Billuart1,2,*

1Institut Cochin, Université Paris Descartes, CNRS UMR8104, 24 rue du Faubourg Saint Jacques 75014, Paris, France, 2INSERM U567, 22 rue Méchain 75014, Paris, France, 3School of Clinical and Experimental Medicine (Neuroscience), The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK and 4DTI- CNR Institute of Neuroscience, 32 via Vanvitelli 20129, Milano, Italy

Received March 2, 2009; Revised and Accepted April 21, 2009

The patho-physiological hypothesis of mental retardation caused by the deficiency of the RhoGAP Oligophrenin1 (OPHN1), relies on the well-known functions of Rho GTPases on neuronal morphology, i.e. dendritic spine structure. Here, we describe a new function of this Bin/Amphiphysin/Rvs domain containing protein in the control of clathrin-mediated endocytosis (CME). Through interactions with Src homology 3 domain containing proteins involved in CME, OPHN1 is concentrated to endocytic sites where it down-regulates the RhoA/ROCK signaling pathway and represses the inhibitory function of ROCK on endocytosis. Indeed disruption of Ophn1 in mice reduces the endocytosis of synaptic vesicles and the post-synaptic α-amino-3-hydroxy-5-methylisoxazol-4-propionate (AMPA) receptor internalization, resulting in almost a complete loss of long-term depression in the hippocampus. Finally, pharmacological inhibition of this pathway by ROCK inhibitors fully rescued not only the CME deficit in OPHN1 null cells but also synaptic plasticity in the hippocampus from Ophn1 null model. Altogether, we uncovered a new patho-physiological mechanism for intellectual disabilities associated to mutations in RhoGTPases linked genes and also opened new directions for therapeutic approaches of congenital mental retardation.

INTRODUCTION

X-linked mental retardation (XLMR) is a genetic disease affecting mostly males. It is characterized by global cognitive impairment and an intelligence quotient below 70 (1). To date, 82 genes have been implicated in XLMR, which display a variety of clinical features. Traditionally, XLMR syndromes have been characterized as either syndromic or non-syndromic dependent on associated clinical abnormalities. Recent clinical re-evaluation of some XLMR cases has, however, suggested that the distinction may not be so clear-cut (2). The distinction between syndromic or non-specific forms of MR is somehow vanishing and some MR cases have been reconsidered after clinical re-evaluation of patients. For example, the non-specific MR gene mental retardation associated with null mutations in Oligophrenin1 (OPHN1) was originally described as non-syndromic (3), but later investigations suggested a syndromic XLMR associated with cerebellar hypoplasia and ventricular dilatation (4–6). We have recently reported that the Ophn1 gene loss of function in mouse displays similarities to the human pathology, apart from the cerebellar hypoplasia, results in dendritic spine immaturity and in altered pre-synaptic function with a reduction of paired-pulse facilitation in CA1 hippocampus (7). These defects may

*To whom correspondence should be addressed. Tel: +33 144412481; Fax: +33 144412421; Email: pierre.billuart@inserm.fr or malik.khelfaoui@inserm.fr

© 2009 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
contribute to the spatial learning impairment in the animal model and presumably to the cognitive deficit in patients with mutations in the Oligophrenin1 gene. However, the function of OPHN1 and its possible involvement in a pathway regulating synaptic transmission is still largely unexplored; as is the question whether the observed alterations in dendritic spine morphology are a cause or consequence of abnormal neurotransmission and/or synaptic activity (8,9).

In this study, we searched for new functions of OPHN1 using a biochemical approach and found that it interacts with molecules involved in clathrin-mediated endocytosis (CME). We next investigated this new function by studying the mouse model of Ophn1 deficiency and found that various cellular mechanisms mediated through CME are impaired in the mutant. At the synapse, OPHN1 loss of function reduces both the synaptic vesicle and α-amino-3-hydroxy-5-methylisoxazol-4-propionate (AMPA) receptor endocytosis affecting synaptic plasticity. Finally, we showed that the RhoA/ROCK signaling pathway is up-regulated in Ophn1 knock-out cells and that pharmacological inhibition of this pathway restores not only the CME deficits, but also the proper synaptic plasticity in Ophn1 mouse model. In addition, these results highlight new patho-physiological mechanisms for intellectual disabilities associated to mutations in RhoGTPases linked genes.

RESULTS

OPHN1 interacts with three molecules involved in CME: amphiphysins, endophilins and CIN85

Apart from the central RhoGAP domain, OPHN1 contains an N-terminal Bin/Amphiphysin/Rvs (BAR) (10) domain followed by a Pleckstrin homology domain and a C-terminal domain with three proline-rich regions at amino acid positions 575, 629 and 740 with multiple Src homology 3 (SH3) binding domains (Fig. 1A) (3,11). Using this latter region as bait in the two-hybrid system, we screened a cDNA library from the fetal brain and found that amphiphysin II (Amphi II), endophilin, Cin85 and synaptophysin, a pre-synaptic protein attached to the synaptic vesicle and mitochondria and crude synaptosomes; S3, cytosolic; P3, microsomal/light membrane compartment; LS1, soluble lysate; P2, synaptosomal/presynaptic plasma membrane; LS2, synaptosomal; LP2, enriched in SV and pre-synaptic plasma membranes. (C) GST pull-down experiments. Purified GST-SH3 domains of CIN85 (ABC), amphiphysin II (Amphi II) or endophilin (EENB1), but not the one from βPIX, are able to strongly bind to OPHN1 protein. Starting material (SM): protein extract at either 1 mg/ml (SM1) or 7 mg/ml (SM7). A 1 mg of protein extract was used for each pull-down experiment; CS: Coomassie staining of SDS–PAGE gel is presented as loading control.

![Figure 1. OPHN1 protein interactions with amphiphysins, endophilins and CIN85. (A) Two-hybrid results from OPHN1 screening using the C-terminal end (LexA-Cter). Black bars show overlapping cDNA clones recovered from the two-hybrid screening (x): number of independent clones recovered from the screening; in all cases, they include at least one SH3 site. BAR: Bin/amphiphysin/Rvs, PH: Pleckstrin Homology, RhoGAP: Rho GTPase activating protein, CC: coiled–coiled, P: proline-rich domains. (B) Rat brain fractionation experiments showing the distribution of OPHN1 together with its binding partners, amphiphysin I and II (Amphi I and II), Cin85 and endophilin. Synaptophysin and SNAP25 were used as positive control of fractionation. Fractions as follows: S1, post-nuclear/cell soma; S2, supernatant; P2, mitochondria and crude synaptosomes; S3, cytosolic; P3, microsomal/light membrane compartment; LS1, soluble lysate; LP1, synaptosomal/pre-synaptic plasma membrane; LS2, synaptosomal; LP2, enriched in SV and pre-synaptic plasma membranes. (C) GST pull-down experiments. Purified GST-SH3 domains of Cin85 (ABC), amphiphysin II (Amphi II) or endophilin (EENB1), but not the one from βPIX, are able to strongly bind to OPHN1 protein. Starting material (SM): protein extract at either 1 mg/ml (SM1) or 7 mg/ml (SM7). A 1 mg of protein extract was used for each pull-down experiment; CS: Coomassie staining of SDS–PAGE gel is presented as loading control.](https://example.com/figure1.png)
from amphiphysin I and II, CIN85 (three SH3 sites ABC) and endophilins (EEN, EEN-B1 and EEN-B2) to test the relative affinity of each EGFP-fused constructs of OPHN1. We found that the first proline-rich region has overlapping binding sites for CIN85 and amphiphysin II and the third proline-rich region binds only endophilins (Fig. 1A and Supplementary Material, Fig. S1A). Among the different partners of OPHN1, amphiphysin I and II and endophilins contain only one SH3 binding site at their C-terminal end, whereas CIN85 has three N-terminal sites A, B and C (Fig. 1A and Supplementary Material, Fig. S1B). We tested in vitro various combinations of GST-fused SH3 sites of CIN85 (constructs A, B and C, Supplementary Material, Fig. S1B) for affinity to OPHN1 CteA protein and found that all three SH3 sites of CIN85 are potentially able to bind independently or in combination to the first proline-rich site of OPHN1 (Supplementary Material, Fig. S1B). Taken together, these data show that OPHN1 interacts with proteins implicated in CME via proline–SH3 binding sites and suggest that OPHN1 plays, through its interactions with these known adaptor molecules, a functional role at endocytic sites.

Loss of OPHN1 leads to the activation of the RhoA/ROCK signaling pathway and reduced receptor endocytosis in various cell types

OPHN1 contains a central RhoGAP domain, which regulates the RhoA/ROCK pathway (11,18). As this pathway has been shown to modulate the receptors endocytosis through endophilin phosphorylation and interaction with CIN85 (26,27), we examined the level of its activation in Ophn1-/- cells. We first studied the activation kinetics of RhoA in serum-stimulated fibroblasts, which results in robust activation of RhoA. Using GST pull-down experiments, we found that total RhoA activity is approximately doubled in Ophn1-/- compared with Ophn1+/- (Supplementary Material, Fig. S2A). We next looked at the activity of the RhoA effector ROCK through quantification of phosphorylation status of one of its substrate, the myosin-binding subunit (MYPT1) of the myosin phosphatase in astroglial cells (28). Ophn1-/- cells presented a significant increase of MYPT1 phosphorylation (x 1.4) compared with Ophn1+/- (Supplementary Material, Fig. S2B; Ophn1+/-: 0.45 ± 0.05; Ophn1-/-: 0.64 ± 0.11; P < 0.05, Mann–Whitney test, MW, n = 4); a phenotype, which could be completely abolished by pre-incubation of the cells with the ROCK inhibitor Fasudil (Supplementary Material, Fig. S2B). These results demonstrated that loss of function of OPHN1 increases the activation of the RhoA/ROCK pathway.

To directly test the consequences of this activation on CME, we performed endocytic assays on primary astroglial cells from both genotypes using fluorescent-labeled transferrin (Tf) or epidermal growth factor (EGF) as tracer of constitutive and endocytotic internalization (Supplementary Material, Fig. S2C; Ophn1+/-: 87 ± 11; Ophn1-/-: 31 ± 4, P < 0.01 two-tailed Student’s t-test n = 4). A similar decrease in EGF receptor internalization was observed in Ophn1-/- fibroblasts using cell-image analyses (data not shown). We next used a specific inhibitor of ROCK, Y27632 (29) to test whether incubation of Ophn1-/- astroglial cells with this drug could abolish the CME deficit. Treatment with Y27632 did not significantly alter endocytosis in Ophn1+/- cells (Supplementary Material, Fig. S2C; Ophn1+/- (-)Y27632: 87 ± 11; Ophn1-/- (+)Y27632: 74 ± 7). This result confirms previous studies showing that ROCK inhibition has no effect on endocytosis in basal conditions (26,30). In contrast, treatment with Y27632 fully rescued the defect in Ophn1-/- cells (Supplementary Material, Fig. S2C; Ophn1-/- (-)Y27632: 31 ± 4; Ophn1-/- (+)Y27632: 84 ± 8; P < 0.01 two-tailed Student’s t-test, n = 4). Thus the activation of the RhoA/ROCK signaling pathway secondary to OPHN1 loss of function is responsible for the reduction of CME in astroglial cells.

Synaptic vesicle endocytosis are reduced in cortical neurons

Since removal of amphiphysins from mouse brain led to some defects in the synaptic vesicles endocytosis (SVE) (31), we tested whether Ophn1 null mice displayed a similar deficit. Using purified synaptosomes from Ophn1+/- and Ophn1-/- mice cortices, we compared the exocytotic and recycling efficiency of synaptic vesicles (SV). High potassium-evoked glutamate release was unaffected in Ophn1-/- synaptosomes (7.1 ± 0.6 versus 6.5 ± 2.1 nmol/mg, P = 0.6, two-tailed Student’s t-test, n = 3). We next employed the fluorescent amphiphatic styryl dye, FM2-10, to study the recycling of SV after two successive depolarization steps by high potassium concentration (32). Using Ca2+ or EGTA containing buffers for unloading steps, we calculated an index called retrieval efficiency (33) to allow direct comparison of recycling between genotypes (Fig. 2A, left panel). We found that the Ca2+-dependent retrieval efficiency was decreased by 17% in Ophn1-/- (Fig. 2A, right panel; Ophn1+/-: 1.82 ± 0.02; Ophn1-/-: 1.42 ± 0.01; P < 0.03, two-tailed Student’s t-test, n = 4). Since the release of glutamate was normal, we hypothesized that Ophn1-/- synapses would have a deficit in the synaptic vesicle endocytosis/recycling. We subsequently used a cellular model to study the uptake of another fluorescent amphiphatic styryl dye, the FM1-43, in individual synapses from cortical neurons after potassium stimulation (34). Whereas there was no effect on synaptic density as measured by the density of the pre-synaptic marker synaptophysin (Ophn1+/-: 385 ± 97; Ophn1-/-: 402 ± 122; P < 0.13, MW test, n = 3), we found that loss of OPHN1 function reduces the density of FM1-43 puncta (−28%) co-localized with synaptophysin (Fig. 2B; Ophn1+/-: 217 ± 95; Ophn1-/-: 157 ± 56; P < 0.02, MW test, n = 3). We also analyzed the internalization of synaptotagmin I as a marker of SV, which undergoes recycling between the pool of SV and pre-synaptic membranes during exocytosis and endocytosis (35). First we determined that the expression of synaptotagmin I was not affected in Ophn1-/- and that it co-localized with the pre-synaptic markers vesicular glutamate transporter-1 (VGLUT1) during resting conditions (data not shown). We then quantified synaptotagmin I antibody uptake in Ophn1+/- and Ophn1-/- neurons (Fig. 2C) after stimulation by high potassium and found that the number of synaptotagmin I positive synapses is decreased in Ophn1-/- cells (−29%) confirming the FM1-43 results (Fig. 2C; Ophn1+/-;
AMPARs from cell surface to intracellular compartments in the hippocampus, and synaptic plasticity in the hippocampus. Loss of OPHN1 affects AMPA receptor endocytosis and synaptic plasticity.

In conclusion, we showed that loss of OPHN1 function reduced the uptake and internalization of various tracers in different models suggesting that OPHN1 contributes to the regulation of a pathway controlling synaptic vesicle endocytosis in a significant fraction of synapses.

**Loss of OPHN1 affects AMPA receptor endocytosis and synaptic plasticity in the hippocampus**

In addition to its localization in the pre-synaptic compartment, OPHN1 is also present at the post-synaptic site (7,11,18), where it could regulate the recycling of various receptors including the AMPA receptors (AMPARs) (36). Translocation of AMPARs from cell surface to intracellular compartments in Ophn1+/y and Ophn1−/y neurons was visualized and quantified by an ‘antibody feeding’ immunofluorescence internalization assay. In Ophn1+/y neurons, the basal endocytosis of GluR1 subunit was rapid, reaching a maximum degree in 5 min without reaching a plateau (Fig. 3A and B and Supplementary Material, Fig. S3). In contrast, in Ophn1−/y neurons, GluR1 subunit endocytosis was significantly down-regulated (Fig. 3A and B and Supplementary Material, Fig. S3), suggesting that OPHN1 contributes in the mechanism controlling the AMPARs trafficking.

Interestingly, this effect was selective of GLUR1 subunit, since GLUR2 internalization rate was not affected by the loss of OPHN1 function (Supplementary Material, Fig. S3).

Current theories suggest that N-methyl-D-aspartic acid (NMDA)-dependent long-term depression (LTD) is a result of AMPAR internalization at the post-synaptic membrane (37,38) via CME (36,39,40). As Ophn1−/y mice display reduced AMPAR internalization in neurons, we hypothesized that LTD may be altered in Ophn1−/y mice. We therefore examined NMDA-dependent LTD at the CA3:CA1 synapse using the extracellular recording technique (Supplementary Material, Fig. S4Bi and Bii). Synaptic responses were recorded in the stratum radiatum of the CA1 region of the hippocampus, and were evoked by stimulation of the Schaffer collateral. Repetitive stimulation at low-frequency (900 pulses, 1 Hz) depressed synaptic responses in Ophn1+/y slices (0.70 ± 0.05, n = 14, P < 0.001, Fig. 4A and Bi), but not Ophn1−/y slices (0.94 ± 0.06, n = 11, P = 0.66, Fig. 4A and Bi). As the reduction in CME in Ophn1−/y astroglial cells was rescued by treatment with the Y27632 ROCK inhibitor (Fig. 3C), we examined whether the observed deficit in the NMDA-dependent LTD was similarly reversed. Y27632 (10 μM) was added to the circulating artificial cerebrospinal fluid (aCSF) for 25 min before, and throughout the LTD protocol and did not alter population synaptic potentials (PSP) amplitude (Supplementary Material, Fig. S4Ai and Aii). In Y27632-treated Ophn1+/y slices, low frequency repetitive stimulation produced LTD (0.62 ± 0.08, n = 5, P < 0.01, Fig. 4Bii), the magnitude of which did not differ from untreated slices (P = 0.61). In contrast, in Ophn1−/y slices, Y27632 revealed that repetitive stimulation
with this mechanism, other activities of ROCK effectors RhoA/ROCK inhibition. Alternatively or in combination the existence of a negative retrocontrol loop of endophilin on concentrates OPHN1 to endocytic sites, this would suggest the endophilin as shown by Kaneko ROCK and consecutive inhibition of CIN85 interaction with a change in its conformation or by an alternative unknown effect could be direct through endophilin phosphorylation by mechanism (41). Activated OPHN1 negatively regulates the BAR domain negatively regulates the RhoGAP activity previously shown that the N-terminal end of OPHN1 containing CME: endophilin, amphiphysin and CIN85. We have prevented SVP (population synaptic potential) slope between 40 and 45 min post-induction protocol. (Bii) To evaluate whether LTD was induced, a one sample Student’s t-test was used (Null whether LTD was induced, a sample Student’s t-test was used (Null hypothesis value was 1, ***P < 0.001, **P < 0.005 and *P < 0.01). Comparisons between control and drug-treated slices were performed using an independent samples t-test (###P < 0.001). The significance value in all tests was set as 0.01, to allow for multiple comparisons.

induced LTD (0.64 ± 0.03, n = 5, P < 0.005, Fig. 4Bii), which significantly differed from untreated slices (P < 0.001). These data therefore support the hypothesis that OPHN1 may also function as a regulator of AMPAR internalization via a ROCK-dependent mechanism of CME.

**DISCUSSION**

Using biochemical and physiological approaches, we identified a new function of OPHN1 in CME through the regulation of Rho GTPase signaling pathways. F-actin bound OPHN1 (11) is recruited to endocytic sites by SH3–proline interactions with three known adaptor molecules involved in CME: endophilin, amphiphysin and CIN85. We have previously shown that the N-terminal end of OPHN1 containing the BAR domain negatively regulates the RhoGAP activity (11). Locally, the increase in OPHN1 concentration would favor its homo-dimerization and/or binding to curved membranes and its RhoGAP activity would be activated by either a change in its conformation or by an alternative unknown mechanism (41). Activated OPHN1 negatively regulates the RhoA/ROCK pathway, repressing the inhibition of this pathway on CME (Supplementary Material, Fig. S5). This effect could be direct through endophilin phosphorylation by ROCK and consecutive inhibition of CIN85 interaction with endophilin as shown by Kaneko et al. (26). As endophilin concentrates OPHN1 to endocytic sites, this would suggest the existence of a negative retrocontrol loop of endophilin on RhoA/ROCK inhibition. Alternatively or in combination with this mechanism, other activities of ROCK effectors such as myosin light chain kinase (42) may be regulated to remodel the actin cytoskeleton during endocytosis.

At the synapse, the differences in synaptosome vesicle cycling between Ophn1+/y and Ophn1−/y suggest deficits in pre-synaptic function. In line with these findings, we previously showed that Ophn1−/y exhibits an impairment in paired-pulse facilitation measured in CA1 hippocampus that could result either from an increase of release probability, a reduction of build-up Ca2+ or a slower rate of SV recycling mechanism (7).

In addition to synaptosome and cellular studies using exogenous and endogenous tracers, impairment in SV cycling was reinforced by electrophysiological studies that showed are a deficit in the size of the pool of readily releasable vesicles together with slower vesicle recycling at the perforant path/dentate gyrus synapses (Powell et al., submitted for publication). These synaptic transmission abnormalities in Ophn1−/y were also rescued by superfusion of hippocampal slices with Y27632 ROCK inhibitor (Powell et al., submitted for publication).

Efficient recycling of SV is required to sustain the high-frequency synaptic transmission observed at synapses, and to maintain structural and functional integrity of the SV pools and presynaptic membrane compartments. Multiple mechanisms of SV recycling have been proposed (43). Direct endocytosis through a clathrin-mediated mechanism account for most of SV recycling under normal and sustained conditions as demonstrated recently by removal of clathrin which severely perturbed SVE in rodent CNS synapses (44).

The efficiency of the SV recycling machinery is important in the formation of a robust memory under challenging conditions. The different SV pools are required for efficient synaptic transmission and short-term memory formation and processing.

The GDI1 gene, responsible in human for X-linked non-specific mental retardation, encodes α-GDI, a regulatory protein common to the Rab GTPases family. In mouse, lack of Rab-GDI perturbed the functionality of different SV pools at the presynaptic site. The reduction in SV did not alter long-term potentiation (LTP) following theta-burst tetanus in the CA1 region of the hippocampus but, as expected, was associated to a decrease in Post-tetanic-potentiation and a delayed recovery of synaptic transmission after depression (45).

In addition to its function in SVE, OPHN1 regulates the endocytosis of AMPARs at the post-synaptic site. Similarly to Arc/Arg3.1 (46,47), OPHN1 loss of function leads to a selective reduction of GLUR1 internalization, whereas the GLUR2 subunit is not affected. The AMPAR internalization experiments were performed in the absence of TTX (Tetrodotoxin). Therefore, in the used conditions of neuronal cell culture, the measured rates of AMPARs correspond to activity-dependant synaptic responses plus constitutive rate of internalization. Previous physiological studies (7) showed no difference in (S)-3,5-dihydroxyphenylglycine (DHPG)-induced LTD measured in CA1 hippocampus suggesting that mGluR-dependent AMPAR internalization is not affected by ophn1 loss of function. However, LFS-induced LTD, which is NMDA dependent, is severely impaired in OPHN1 KO. Altogether, these results from cellular and physiological studies suggest that activity-induced internalization of AMPAR is reduced in the ophn1 KO, affecting the GLUR1 subunit but not GLUR2. Previous studies have shown that in
mature hippocampal pyramidal cells, AMPARs occur predominantly as complexes containing GluR1/2 or GluR2/3 (48). The current model of AMPAR trafficking suggests that AMPARs containing GluR1 are inserted into synapses in an activity-dependent manner, whereas GluR2/3 heteromers cycle constitutively into and out of synapses (49). Since both subunits are internalized through CME, this would suggest that either OPHN1 controls the selective endocytosis of GLUR1 homomers or loss of OPHN1 function leads to secondary changes of the AMPAR subunit composition with a shift toward more GLUR2-lacking AMPARs. Alternatively, the selectivity for a pool of AMPAR may depend on the rate at which the receptors cycle into and out of the synapse (50).

What could be the physiological consequences of these changes? We have previously reported that LTP and mGLUR1-dependant LTD were not modified in the Ophn1<sup>−/−</sup> hippocampus (7). Here we found that NMDAR-dependant LTD is barely induced by low-frequency stimulation. Although both forms of LTD are mediated by the endocytosis of AMPAR, the signaling cascades that support each LTD are distinct. For instance, DHPG (mGLUR1 agonist)-stimulated LTD involved the local synthesis of Arc/Arg3.1 protein that binds to endophilins and dynamin, promoting AMPAR endocytosis (51,52). We can speculate that either OPHN1 is not involved in the cascade mediating mGLUR1-LTD or that Arc/Arg3.1 compensate for OPHN1 deficiency for this specific form of LTD.

Taken together, these compelling results suggest that part of the intellectual disability in OPHN1 patients is a consequence of abnormal synaptic transmission linked to enhanced RhoA/ROCK activation and reduced endocytosis. Thus it might be possible to correct this deficit by reducing Rho GTPase expression in astroglial cells from Ophn1<sup>−/−</sup> mice, but also restore synaptic transmission and plasticity in Ophn1<sup>−/−</sup> hippocampal neurons. An exciting implication of this discovery is that drugs targeting Rho-kinases or others Rho GTPases effectors might be therapeutically useful for Rho GTPases linked mental retardations, assuming that they share a common patho-physiological mechanism.

**MATERIALS AND METHODS**

**Primary cell culture and animals**

Experimental procedures were performed in accordance with the European Communities Council Directive (86/809/EEC) regarding the care and use of animals and were approved by the local Ethics Committee. Cortical neurons, fibroblasts and astroglial cells from Ophn1<sup>−/−</sup> knock-out animals and wild-type controls in C57BL/6 background were prepared by standard procedures as previously described (7).

**Two-hybrid screening**

A fetal brain matchmaker cDNA library (Cat# HL4028AH, lot# 7110056 from Clontech CA, USA) was screened with a bait consisting of the human OPHN1 cDNA BglII/Sall fragment (amino acid 563–802) in VJL9 vector derived from pBTM116 (LexA binding domain); the yeast strain L40 (53) was maintained according to standard protocols (54). Out of 50 recovered cDNA clones from 1 million screened, 22 corresponded to amphiphysin II, 10 clones to endophilin genes (EEN-B1 and B2), and two clones to CIN85 protein.

**GST pull-down**

GST-tagged SH3 proteins were expressed in BL21 bacterial cells (Promega, WI, USA) and affinity purified according to standard protocols (55). Cos-1 cells were transfected using Lipofectamine (Invitrogen, CA, USA) with the following constructs: GFP-Cter, BglII/Sall (amino acid 563–802) in pEGFP-CD11 (Clontech), GFP-Cter A BglII/PstI (amino acid 563–677) in pEGFP-CD11, GFP-Cter B PstI/Sall (amino acid 677–802) in pEGFP-C3 (Clontech). Transfected proteins were detected with anti-GFP monoclonal antibody.

**RhoA and ROCK activation assay**

RhoA activation was assayed by western blotting cell extracts according to manufacturer's instructions (Cytoskeleton, CO, USA).

Rho-kinase activity was quantified by MYPT1 phosphorylation on Thr-853 by western blot analyses starting from astroglial cells protein extracts. The ratio of phospho-MYPT1 against total MYPT1 density was calculated after quantification using densitometric analysis with ImageJ software.

**Brain fractionation and preparation of synaptosomes**

Rat brain from one adult male was processed according to protocols from (56), 75 µg of proteins were loaded on 5–15% gradient SDS–PAGE gel for Western blot experiment. Synaptosomes from five to seven cerebral cortices of adult mice were prepared by centrifugation on discontinuous percoll gradients as previously described (32,57).

**Glutamate exocytosis and content**

The glutamate release was performed by enzymatic assay using the glutamate dehydrogenase as previously described using 1 mg of purified synaptosomes (58). The total glutamate content of 0.5 mg purified synaptosomes was determined after complete lysis and extraction in 0.1% Triton by the same method described above. The fluorescence intensities were acquired using a thermostated Cary Eclipse fluorescence spectrophotometer (Varian, CA, USA).

**Synaptosome FM2-10 recycling**

Two milligram of purified synaptosomes was loaded at 37°C with 100 µM FM2-10 (Molecular Probes, OR, USA) by depolarization with 30 mM KCl for 90 s in the presence of 1.3 mM Ca<sup>2+</sup> as previously described (32,57). After two washes in low K+ saline solution with 1 mg/ml BSA, 1 mg of labeled synaptosomes were unloaded by a second 30 mM KCl induced depolarization in the presence of 1.3 mM Ca<sup>2+</sup>.
or 2 mM EGTA. Depending of the presence of Ca\(^{2+}\) (Ca\(^{2+}\)+Ca\(^{2+}\) or Ca\(^{2+}\)EGTA), we obtained two values of fluorescence that allowed us to calculate an index called retrieval efficiency \([RE = Ca/Ca/(CaCa–CaEGTA)]\) (33). By dividing the amount of endocytosis by exocytosis, this ratio bypasses the variability linked to synaptosomal purification and allowed us to quantitatively compare independent preparations from both genotypes.

**FM1-43 uptake in cultured neurons**

Synapses from individual cortical neurons were labeled with FM1-43 (Molecular Probes) according to Mozhamiya et al. (59). Neurons were then washed in a Tyrode buffer for 10 min and fixed in 4% paraformaldehyde/0.2% glutaraldehyde in PBS for 10 min. After fixation, cells were incubated with VGlut-T et synaptophysin antibodies for detection of all synapses. Thirty-five neurons from each genotype were acquired with identical imaging conditions and analyzed similarly. Analyses were performed by quantification of the number of FM1-43 punctae co-localized with synaptophysin and normalized to the neuron surface. The experiment was repeated three times with similar results.

**Synaptotagmin uptake in cultured neurons**

Endocytosis of synaptotagmin1 antibody at steady state or after potassium-induced exocytosis was tested according to Takei et al. (35). Briefly, neurons were incubated at 37°C for 30 min with SytLum–Abs (SynSyst antibody) mouse monoclonal antibody, directed to the luminal domain of synaptotagmin and stimulated with 90 mM KCl for 2 min. Neurons were then washed and fixed before staining for synaptotagmin cytoplasmic domain antibody (SynSyst), rabbit polyclonal antibody to visualize the total of synaptotagmin vesicles pool. Twenty neurons from each genotype were acquired with identical imaging conditions and analyzed similarly. Positive synapses for SytLum antibody were normalized to the neuron surface. The experiment was repeated twice with similar results.

**EGF and Tf uptake**

Receptor-mediated endocytosis was analyzed by assays for EGF and Tf uptake as previously described (60). Adherent cells (fibroblasts or astroglial) were incubated with 15 µg/ml FITC-labeled Tf for 10 min at 37°C. Labeled cells were washed and re-suspended in medium after trypsin application and immediately put on ice for FACS analysis.

For rescue assays, cells were serum starved during 2 h in presence of 10 µM Y27632 (Sigma, MO, USA) (29) before incubation with labeled transferrin. Flow cytometry measurements of at least 5000–10 000 cells per sample were analyzed using Cellquest software on a FACScalibur (BD Biosciences, CA, USA). Fluorescent values from untreated *Ophn1*\(^{+/+}\) are set to 100 and other conditions are expressed as percentage of Tf receptor uptake normalized to untreated *Ophn1*\(^{+/+}\).

**AMPAR internalization assay**

Live hippocampal neurons at 15–18 days *in vitro* were labeled for 10 min at 37°C with an antibody directed against the extra-cellular region of either GluR1 or GluR2. After washing in PBS, 1 mM MgCl\(_2\) and 0.1 mM CaCl\(_2\) (PBS+MC), neurons were incubated at 37°C in conditioned growth medium for different times (0, 5, 10, 15, 20 min). Neurons were fixed for 5 min at room temperature in 4% paraformaldehyde/4% sucrose without permeabilization, and stained with FITC conjugated secondary antibodies for 1 h at room temperature, to visualize pre-labeled surface receptors. Neurons were then permeabilized for 1 min in 100% methanol at −20°C and stained with Cy3-conjugated secondary antibodies for 1 h at room temperature in DGB buffer (permeabilizing conditions: 30 mM phosphate buffer pH 7.4 containing 0.2% gelatin, 0.5% Triton X-100 and 0.8 mM NaCl), to visualize pre-labeled internalized receptors. Red fluorescence average intensities indicative of internalization were divided by total average (red + green) fluorescence intensities to control (time 0) for synaptic density.

**Image acquisition and analysis**

Fluorescence images were acquired using a coolSnap digital camera (Roper Scientific) or a Photometrics CCD camera (Princeton Instruments, Trenton, NJ, USA). Acquired image sequences were saved as stacks of 16 bit TIFF files and analyzed with ImageJ software (http://rsb.info.nih.gov/ij/) or Metamorph software (Universal Imaging Corporation, West Chester, PA, USA).

**Antibodies**

The following primary antibodies were used: amphiphysins and endophilins kindly provided by Pietro Camilli, CIN85 (cat#231006 from Calbiochem, Darmstadt, Germany), PAK3 (cat#SC1871-N19 from Santa Cruz, CA, USA), OPHN1 (cat#SC8374-C19 Santa Cruz), GFAP (cat#1814460 from Roche, Mannheim, Germany), Synaptophysin (cat#VAM-SV011 from StressGen, Canada), SNAP25 (cat#VAM-SV012 from StressGen, Canada), VGlut-1 kindly provided by S. El Mestikawy and B. Giros, GFAP (cat# sc-6170 from Santa Cruz), Tubulin (cat# T 6074 from Sigma), anti-MYPT1 antibody (cat#990407 from Upstate, NY, USA) and antiphospho-MYPT1 Thr853 (cat#36-003 from Upstate), GluR1 (Oncogene Research Products, Cambridge, MA, USA) or GluR2 (Chemicon International, Temecula, CA, USA). Fluorescent-conjugated secondary antibodies were purchased from Jackson ImmunoResearch Labs, (West Grove, USA).

**Electrophysiology**

Mice were anaesthetized by intraperitoneal injection of a mixture of medetomidine (1 mg/kg) and ketamine (76 mg/kg) prior to being killed by cervical dislocation, their brains removed for preparation of 400 µm ventral slices of the dorsal hippocampus slices using a VibroSlice (Campden Instruments, Loughborough, UK). Slices were placed in an interface recording chamber perfused with aCSF containing...
(in mM): 125 NaCl, 26 NaHCO3, 1.25 NaH2PO4, 3 KCl, 2 CaCl2, 1 MgCl2 and 10 Glucose, pH 7.4, gassed with 95% O2, 5% CO2, maintained at 32°C. Slices were allowed to recover for a period of 1 h prior to recording.

Stimuli were applied through a concentric stimulating electrode (Harvard Apparatus, Edenbridge, UK) placed in the stratum radiatum ~150 µm from the CA1 pyramidal cell layer. Recordings of PSP were made from the same layer of stratum radiatum, ~2 mm away, using glass microelectrodes, an Neurolog DC amplifier and a 1401plus signal acquisition system running Signal version 3.10 (Cambridge Electronic Design, Cambridge, UK). Stimulus response curves used a fixed set of stimulus strengths and the field PSPs were measured as the slope (between 20 and 80% of maximum. LTD was induced by 900 stimuli delivered at 1 Hz after at least 15 min of recording half maximal stimuli delivered every 60 s. The same test stimuli were then delivered for a further 45 min.

Statistical analyses
Microsoft Excel (Microsoft) with StatEL plugin from AdScience (France) was used for statistical analyses. All results are given as mean ± SEM unless otherwise stated. All probability values are given for an alpha level of 5% using MW as non-parametric test or two-tailed, unpaired Student’s t-tests for analyses of data from synaptosomes.

SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS
We thank L. Bongiorno-Borbonne, C. Randriamampta, P. Petit and P. Bourdoncle for sharing their expertise, respectively, in brain fractionation and synaptosomal preparation (L.B.-B.), in the use of the Spectrofluorimeter (C.R.), in flow cytometry (P.P.) and image analyses (P.B.). We also thanks the following scientists for providing us with various GST-SH3 constructs: EENB1 and 2 from E. Chi Wai, amphiphysin 1 and 2, intersecting SH3 domains from P. McPherson, CIN85 from S. Kajigaya, Nck from B. Mayer and betaPIX from D. Park. Finally we thank D. Soret, C. Moraine, S. Marty, T. Gali, G. Di Paolo and M. Cousin for sharing unpublished data, discussions and scientific support.

Conflict of Interest statement. None declared.

FUNDING
This work was supported by INSERM, ANR05-Neuro-040-01, Foundation Jérôme Lejeune, Association Française contre la Myopathie, Fondation Rercheche Médicale, Wellcome Trust and European grants (QLG3-CT-2002-01810). Funding to pay the Open Access charge was provided by the Fondation Jérôme Lejeune.

REFERENCES


